Liberty Wealth Management LLC recently announced the acquisition of new stake in Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI). The institutional investor has increased its shareholding in the Healthcare company by 134.22% to 0.35 million shares with purchase of 0.2 million shares. This fresh investment now brings its stake to 0.72% valued currently at $98381.0. In addition, Geode Capital Management LLC raised its holdings by 35071.0 to 0.31 million shares.
With over 23.38 million Brainstorm Cell Therapeutics, Inc. (BCLI) shares trading Tuesday and a closing price of $0.23 on the day, the dollar volume was approximately $5.38 million. The shares have shown a negative half year performance of -89.30% and its price on 12/26/23 gained nearly 16.40%. Currently, there are 48.98M common shares owned by the public and among those 40.35M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for BCLI have a consensus price objective of $10.00. The analysts have set the share’s price value over the next 12 months at a high of $10.00 and a low of $10.00. The average price target is 97.7% above its recent price level and an upside to the estimated low will see the stock gain 97.7% over that period. But an upside of 97.7% will see the stock hit the forecast high price target while median target price for the stock is $10.00.
Insiders at the company have transacted a total of 7 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 7 of these insider trades were purchases, accounting for 274,684 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Brainstorm Cell Therapeutics, Inc. are Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and iShares Tr. – Micro Cap ETF. Vanguard Total Stock Market ETF owns 0.95 million shares of the company’s stock, all valued at over $0.27 million. iShares Tr. – Micro Cap ETF now owns shares totaling to 0.17% of the shares outstanding.
Shares of Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) opened at $0.2421, up $0.04 from a prior closing price of $0.20. However, the script later moved the day high at 0.2500, up 16.40%. The company’s stock has a 5-day price change of 7.63% and -46.22% over the past three months. BCLI shares are trading -85.98% year to date (YTD), with the 12-month market performance down to -87.50% lower. It has a 12-month low price of $0.13 and touched a high of $3.46 over the same period. BCLI has an average intraday trading volume of 3.42 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.09%, 15.48%, and -85.05% respectively.
Institutional ownership of Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) shares accounts for 9.88% of the company’s 48.98M shares outstanding. Mutual fund holders own 3.42%, while other institutional holders and individual stakeholders account for 6.45% and 11.53% respectively.
It has a market capitalization of $11.27M and a beta (3y monthly) value of 0.17. The earnings-per-share (ttm) stands at -$0.44. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.65% over the week and 20.55% over the month.
Analysts forecast that Brainstorm Cell Therapeutics, Inc. (BCLI) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and -$0.47 for 2024. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$0.19 a year ago. Earnings per share for the fiscal year are expected to increase by 18.18%, and 14.81% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Brainstorm Cell Therapeutics, Inc. (BCLI) as a “Strong Buy” at a consensus score of 1.00. Specifically, 0 Wall Street analysts polled rate the stock as a buy, while 1 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the BCLI, a number of firms have released research notes about the stock. Maxim Group stated their Buy rating for the stock in a research note on February 04, 2021, with the firm’s price target at $12.
